摘要
目的探讨^(131)I 治疗 Graves 甲状腺功能亢进症(简称甲亢)中动态监测血清促甲状腺激素受体抗体(TRAb)水平变化的临床价值。方法 130例 Graves 甲亢患者和50名健康对照者分别于^(131)I 治疗前及治疗后3,6,12和24个月采用放射受体分析法(RRA)测定其血清 TRAb 水平。数据用 x^-±s表示,组间差异用方差分析与 t 检验。结果 130例 Graves 甲亢患者在^(131)I 治疗前血清 TRAb水平[(92.93±68.99)U/L]高于健康对照组(P<0.01)。在^(131)I 治疗后3个月血清 TRAb 水平[(139.04±77.19)U/L]明显高于治疗前(P<0.01),治疗后6个月患者血清 TRAb 水平[(65.87±54.86)U/L]开始降低,但与对照组比较差异仍有统计学意义(P<0.01),在^(131)I 治疗12个月后血清TRAb 水平[(14.16±12.35)U/L]明显降低(P<0.01),到24个月患者血清 TRAb 水平[(12.99±5.52)U/L]与对照组比较差异无统计学意义(P>0.05)。结论在^(131)I 治疗前检测血清 TRAb 水平可指导^(131)I 的用量;在^(131)I 治疗后检测 Graves 甲亢患者的 TRAb 水平有助于随访监测及疗效评价,还可了解治疗后的免疫反应状态。
Objective The clinical value of thyrotrophin receptor antibody （TRAb） in patients with Graves＇ hyperthyroidism was investigated during ^131I radiotherapy. Methods A total of 130 patients with Graves＇ hyperthyroidism and 50 normal controls were included in the study. Serum concentration of TRAb was measured by radioreceptor assay （RRA） before and at 3, 6, 12 and 24 months after ^131I radiotherapy. Results Abnormally higher TRAb level [ （92.93 ± 68.99） U/L] was noted in patients before treatment（ P 〈 0.01 ）. The TRAb titer increased further to （ 139.04 ± 77.19） U/L at 3 months after therapy （ P 〈 0.01 ）, before it dropped to （65.87 ± 54.86） U/L and （ 14.16 ± 12.35 ） U/L at 6 and 12 months respectively. At 24 months after ^131I radiotherapy, the TRAb [ （ 12.99 ±5.52） U/L] was back to normal with no difference to that of controls （ P 〉 0.05 ）. Conclusion Serum concentration of TRAb was of clinical significance in the diagnosis of Graves＇ hyperthyroidism and in the monitoring of ^131 I radiotherapy.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2007年第5期295-296,共2页
Chinese Journal of Nuclear Medicine
